Editor’s note: This is a developing news story. Please check back soon for updates.
Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a press release from Biocon.
The FDA approved Yesafili (aflibercept-jbvf) in May 2024. It is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
In the phase 3 INSIGHT study, researchers compared Yesafili with Eylea 2 mg (aflibercept, Regeneron) in patients with DME. There were no differences